Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.

Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.

Abstract: Provided is a novel APP (amyloid precursor protein) transgenic non-human animal modeling in vivo the pathophysiological effects and effects on cognitive behavior of early intraneuronal and extracellular brain parenchymal amyloid-? (A?) deposition and cerebral amyloid angiopathy associated with brain microhemorrhages and reduced vasoreactivity and blood flow. Furthermore, methods of screening for therapeutic or diagnostic agents useful in the treatment or diagnosis of Alzheimer's disease, in particular for improving blood flow to the brain are provided as well as the corresponding therapeutic methods.

Abstract: The present description relates generally to methods of using Abeta binding molecules including, for example, antibodies and antibody fragments that recognize Abeta. The description provides methods of promoting neurogenesis, angiogenesis, synaptic activity and/or dendritic arborization using Abeta binding molecules. The description also provides methods of treating various diseases, disorder, injuries and conditions associated with amyloid plaques or the accumulation of Abeta.

Abstract: Provided are novel tumor-specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize tumor-associated antigens and that are obtained from a tumor patient who shows at least partial clinical response or is symptom-free. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of tumors are described.

Abstract: Provided are novel a target and drugs in the treatment of neurological disorders related to amyloid beta pathology/amyloidosis. More specifically, the use of phosphatase inhibitors for the treatment of brain impairments mediated by A?-oligomers is described.

Abstract: The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerisation of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.

Abstract: Provided are novel human tumor-specific antibodies as well as fragments, derivatives and variants thereof that recognize tumor-associated antigen NY-ESO-1. In addition, pharmaceutical compositions comprising such antibodies and mimics thereof in the treatment of tumors are described.

Abstract: A novel treatment of Alzheimer's disease and other disorders involving protein misfolding or aggregation is provided by enhancing or sustaining an antibody response against predominantly directed against pathological protein aggregates or neo-epitopes present on pathogenic forms of said protein or protein complex. Furthermore, therapeutic methods are also described, wherein ex vivo stimulated antigen-selected peripheral blood lymphocytes are regrafted into the cognate donor.

Abstract: A monoclonal antibody against beta-amyloid (ABeta) peptide is provided with unique immunological and biological properties useful in the immunotherapy of Alzheimer's disease. In addition, pharmaceutical compositions and kits comprising such antibody and mimics thereof in the treatment of neurological disorders such as Alzheimer's disease are described.

Abstract: Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.

Abstract: Provided are novel drugs and methods in the treatment as well as diagnosis of neurological disorders such as Alzheimer's disease and amyloid-beta pathology/amyloidosis. More specifically, the use of erythropoietin and analogs thereof for the treatment of A? peptide related brain impairments is described. Furthermore, the use of claudin-5 and variants thereof as biomarker for Alzheimer's disease and for the progression of Alzheimer's disease, respectively, is provided.

Abstract: A novel method of identifying and obtaining molecules interacting with neurodegenerative, neurological or neuropsychiatric disorder-associated proteins is provided, which is suitable for drug screening and drug development. Furthermore, drugs and drug targets for the therapeutic intervention of neurodegenerative, neurological or neuropsychiatric disorders, in particular Alzheimer's disease are described.

Abstract: Provided are novel a target and drugs in the treatment of neurological disorders related to amyloid beta pathology/amyloidosis. More specifically, the use of phosphatase inhibitors for the treatment of brain impairments mediated by A?-oligomers is described.

Abstract: The present invention discloses a method and an in-vivo assay system useful for the identification and testing of modulating agents as well as for the validation of therapies of neurodegenerative diseases associated with the formation of neurofibrillary tangles, in particular Alzheimer's disease. The present invention is based on the surprising finding that injection of ?-amyloid A?42 fibrils into brains of P301L mutant tau transgenic mice caused several-fold increases in the numbers and an accelerated production of neurofibrillary tangles in cell bodies predominantly within the amygdala. The induced neurofibrillary tangles occurred as early as 18 days after A?42 injections and displayed striking features of neurofibrillary tangles of several human neurodegenerative diseases, particularly Alzheimer's disease.

Abstract: Provided is a novel APP (amyloid precursor protein) transgenic non-human animal modeling in vivo the pathophysiological effects and effects on cognitive behavior of early intraneuronal and extracellular brain parenchymal amyloid-? (A?) deposition and cerebral amyloid angiopathy associated with brain microhemorrhages and reduced vasoreactivity and blood flow. Furthermore, methods of screening for therapeutic or diagnostic agents useful in the treatment or diagnosis of Alzheimer's disease, in particular for improving blood flow to the brain are provided as well as the corresponding therapeutic methods.

Abstract: A method for diagnosing or prognosing Alzheimer's disease in a subject, or determining whether a subject is at increased risk of developing Alzheimer's disease, comprising: determining a level, or an activity, or both said level and said activity, of transcription product and/or a translation product of (i) a cystatin C gene or (ii) a polymorphic variant of a cystatin C gene in a sample from said subject; and comparing said level, or said activity, or both said level and said activity, of said transcription product and/or said translation product to a reference value representing a known disease or health status, thereby diagnosing or prognosing Alzheimer's disease in said subject, or determining whether said subject is at increased risk of developing Alzheimer's disease.

Abstract: The present invention discloses a method and an in-vivo assay system useful for the identification and testing of modulating agents as well as for the validation of therapies of neurodegenerative diseases associated with the formation of neurofibrillary tangles, in particular Alzheimer's disease. The present invention is based on the surprising-finding that injection of ?-amyloid A?42 fibrils into brains of P301L mutant tau transgenic mice caused several-fold increases in the numbers and an accelerated production of neurofibrillary tangles in cell bodies predominantly within the amygdala. The induced neurofibrillary tangles occurred as early as 18 days after A?42 injections and displayed striking features of neurofibrillary tangles of several human neurodegenerative diseases, particularly Alzheimer's disease.

Abstract: The invention discloses an isolated nucleic acid molecule encoding a protein molecule, the function of which is to protect cells against degeneration and/or cell death, wherein the amino acid sequence of the protein comprises the sequence shown in SEQ ID NO. 2 or a functional variant thereof.

Abstract: The invention relates to a method for diagnosing or prognosing depression, in particular major depression, in a subject, or determining whether a subject is at increased risk of developing depression, in particular major depression, comprising: determining a level, or an activity, or both said level and said activity, of neurotrophin 3 and/or of a transcription product of a gene coding for neurotrophin 3 in a sample from said subject; and comparing said level, or said activity, or both said level and said activity, to a reference value representing a known disease or health status, thereby diagnosing or prognosing depression in said subject, or determining whether said subject is at increased risk of developing said depression.